Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Claret Targets TAVR Stroke Risk With Sentinel Embolic Filter Device

This article was originally published in The Gray Sheet

Executive Summary

The company launched the SENTINEL trial in the U.S., the first prospective, randomized, controlled, blinded trial in the U.S. of a cerebral protection device for transcatheter aortic valve replacement.

You may also be interested in...



News Briefs: Panel OKs Sleep Apnea Stimulator; Two Stryker Buys; TAVR Updates

FDA panel unanimously endorses Inspire upper airway stimulator. Stryker buys Berchtold and Pivot. First randomized U.S. study of embolic protection during transcatheter aortic valve replacement approved. More news.

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.

Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings

Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel